These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 17097964)

  • 21. Conversion to rapamycin immunosuppression for malignancy after kidney transplantation.
    Manuelli M; De Luca L; Iaria G; Tatangelo P; Sforza D; Perrone L; Bellini MI; Angelico R; Anselmo A; Tisone G
    Transplant Proc; 2010 May; 42(4):1314-6. PubMed ID: 20534289
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Sirolimus therapy after early cyclosporine withdrawal reduces the risk for cancer in adult renal transplantation.
    Campistol JM; Eris J; Oberbauer R; Friend P; Hutchison B; Morales JM; Claesson K; Stallone G; Russ G; Rostaing L; Kreis H; Burke JT; Brault Y; Scarola JA; Neylan JF
    J Am Soc Nephrol; 2006 Feb; 17(2):581-9. PubMed ID: 16434506
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Sirolimus-based immunosuppressive therapy in liver transplant recipient with tacrolimus-related chronic renal insufficiency.
    Yang YJ; Chen DZ; Li LX; Kou JT; Lang R; Jin ZK; Han DD; He Q
    Transplant Proc; 2008 Jun; 40(5):1541-4. PubMed ID: 18589147
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Incidence of posttransplant diabetes mellitus in kidney transplant recipients immunosuppressed with sirolimus in combination with cyclosporine.
    Romagnoli J; Citterio F; Nanni G; Favi E; Tondolo V; Spagnoletti G; Salerno MP; Castagneto M
    Transplant Proc; 2006 May; 38(4):1034-6. PubMed ID: 16757255
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Switching to sirolimus in renal transplant recipients with hepatitis C virus: a safe option.
    Gallego R; Henriquez F; Oliva E; Camacho R; Hernández R; Hortal L; Sablón N; Quintana B; Santana R; Gonzalez F; Palop L; Vega N
    Transplant Proc; 2009; 41(6):2334-6. PubMed ID: 19715912
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Conversion to sirolimus in pediatric renal transplantation recipients.
    Garcia CD; Bittencourt VB; Alves AB; Garcia VD; Tumelero A; Antonello JS; Malheiros D
    Transplant Proc; 2006; 38(6):1901-3. PubMed ID: 16908317
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A retrospective study of conversion from tacrolimus-based to sirolimus-based immunosuppression in orthotopic liver transplant recipients.
    Yu S; He X; Yang L; Ma Y; Zhu X; Ju W; Huang J
    Exp Clin Transplant; 2008 Jun; 6(2):113-7. PubMed ID: 18816237
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Where did we leave off in 2008? Conclusions from the 8th International Symposium.
    Russ G
    Transplant Proc; 2009; 41(6 Suppl):S27-30. PubMed ID: 19651292
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Different profile of gene expression of cytokines in peripheral blood mononuclear cells of transplant recipients treated with m-TOR inhibitor and calcineurin inhibitor.
    Niemczyk M; Zegarska J; Pawłowska M; Wyzgał J; Ciszek M; Paczek L
    Transpl Immunol; 2009 Jan; 20(3):139-42. PubMed ID: 18834941
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Sirolimus experience in heart transplantation.
    Aranda-Dios A; Lage E; Sobrino JM; Mogollón MV; Guisado A; Cabezón S; Hinojosa R; Hernández A; Ordóñez A
    Transplant Proc; 2006 Oct; 38(8):2547-9. PubMed ID: 17097997
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Protocol conversion from a calcineurin inhibitor based therapy to sirolimus.
    Oberbauer R
    Transplantation; 2009 Apr; 87(8 Suppl):S7-10. PubMed ID: 19384186
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Five-year follow-up after late conversion from calcineurin inhibitors to sirolimus in patients with chronic renal allograft dysfunction.
    Krüger B; Fischereder M; Jauch KW; Graeb C; Hoffmann U; Böger CA; Banas B; Obed A; Schlitt HJ; Krämer BK
    Transplant Proc; 2007 Mar; 39(2):518-21. PubMed ID: 17362772
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Sirolimus-based immunosuppression after cardiac transplantation: predictors of recovery from calcineurin inhibitor-induced renal dysfunction.
    Gustafsson F; Ross HJ; Delgado MS; Bernabeo G; Delgado DH
    J Heart Lung Transplant; 2007 Oct; 26(10):998-1003. PubMed ID: 17919619
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Two-year incidence of malignancy in sirolimus-treated renal transplant recipients: results from five multicenter studies.
    Mathew T; Kreis H; Friend P
    Clin Transplant; 2004 Aug; 18(4):446-9. PubMed ID: 15233824
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Factors influencing glomerular filtration rate in renal transplantation after cyclosporine withdrawal using sirolimus-based therapy: a multivariate analysis of results at five years.
    Legendre C; Brault Y; Morales JM; Oberbauer R; Altieri P; Riad H; Mahony J; Messina M; Pussell B; Martínez JG; Lelong M; Burke JT; Neylan JF;
    Clin Transplant; 2007; 21(3):330-6. PubMed ID: 17488381
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Sirolimus conversion in liver transplant recipients with renal dysfunction: a prospective, randomized, single-center trial.
    Shenoy S; Hardinger KL; Crippin J; Desai N; Korenblat K; Lisker-Melman M; Lowell JA; Chapman W
    Transplantation; 2007 May; 83(10):1389-92. PubMed ID: 17519792
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Is sirolimus responsible for proteinuria?
    Dervaux T; Caillard S; Meyer C; Ellero B; Woehl-Jaegle ML; Hannedouche T; Wolf P; Moulin B
    Transplant Proc; 2005; 37(6):2828-9. PubMed ID: 16182822
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Conversion to rapamycin immunosuppression for malignancy after kidney transplantation: case reports.
    Iaria G; Anselmo A; De Luca L; Manuelli M; Lucchesi C; Tariciotti L; Monaco A; Sforza D; Nigro F; Abruzzese E; Tisone G
    Transplant Proc; 2007; 39(6):2036-7. PubMed ID: 17692685
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Addition of sirolimus to cyclosporine in long-term kidney transplant recipients to withdraw steroid.
    Citterio F; Sparacino V; Altieri P; Rigotti P; Calabrese S; Poli M; Vinti V; Segoloni GP
    Transplant Proc; 2005 Mar; 37(2):827-9. PubMed ID: 15848545
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Characteristics of neoplasm occurrence and the therapeutic effect of sirolimus in South Chinese kidney transplant recipients.
    Wang CX; Liu LS; Chen LZ; Chen SY; Wu PG; Fei JG; Qiu J; Deng SX; Zheng KL; Ji YL; Zhu LY; Shen QR; He XS
    Transplant Proc; 2006 Dec; 38(10):3536-9. PubMed ID: 17175325
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.